New hope for hemophilia a: Low-Dose emicizumab may beat standard therapy for joint protection
NCT ID NCT07439055
First seen Mar 19, 2026 · Last updated May 22, 2026 · Updated 12 times
Summary
This study looks at whether a low dose of emicizumab works better than standard factor VIII therapy for controlling bleeding and protecting joints in people with hemophilia A. Eighteen patients aged 8-28 who were already on factor VIII but still had joint problems switched to low-dose emicizumab. Researchers will track bleeding rates, joint health scores, and quality of life over 8 months to see if the switch leads to better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A PATIENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chulalongkorn University
Bangkok, 10330, Thailand
Conditions
Explore the condition pages connected to this study.